Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial)
Gespeichert in:
Verfasser / Beitragende:
[R. Rahmé, L. Ades, X. Thomas, A. Guerci-Bresler, A. Pigneux, N. Vey, E. Raffoux, S. Castaigne, O. Spertini, S. Wittnebel, J.P. Marolleau, G. Damaj, D. Bordessoule, J. Lejeune, S. Chevret, P. Fenaux]
Ort, Verlag, Jahr:
2018
Enthalten in:
Haematologica, 103/11(2018-11), e519-e521
Format:
Artikel (online)